Period 1 (first prescription date of thiamazole (t0) ~ 2nd weeks after t0) Number of target patients Period 2 (3 – 4th weeks after t0) Number of target patients Not Conducted † All Conducted † Period 3 (5 – 6th weeks after t0) Number of target patients Not Conducted † Partly Conducted † All Conducted † Period 4 (7 – 8th weeks after t0) Number of target patients Not Conducted † Partly Conducted † All Conducted † Number of patients Patients with granulocytopenia n (%) 4,371 ( 100%) 4,070 ( 100%) 1,758 (43.2%) 2,312 (56.8%) 3,887 ( 100%) 1,092 (28.1%) 1,607 (41.3%) 1,188 (30.6%) 3,426 ( 100%) 727 (21.2%) 1,962 (57.3%) 737 (21.5%) Proportion 141 3.2 62 20 42 1.5 1.1 1.8 38 <18* <18* 20 1.0 <2.0* <2.0* 1.7 30 <10* 55.22 ) 20 71.00 ) <10* * When a value was < 10, it was shown as an aggregated value based on the MID-NET® publication rule. † Patients who had not undergone blood test in all previous periods (“Not Conducted”) and who had undergone 0.9 <2.0* 1.0 <2.0* Age and sex adjusted odds ratio (95% confidence interval) % % % % 1.00 1.63 ( % % % % 1.00 2.36 4.64 ( ( % % % % 1.00 7.40 8.97 ( ( Reference - 0.95 2.78 ) Reference - - 0.77 1.58 7.19 ) 13.63 ) Reference - - 0.99 1.13 19 < Impact on RS, expectations > The utilization of medical information database, such as MID-NET®, allows us to conduct a study reflecting a situation of actual clinical practice (real world). We consider that conducting pharmacoepidemiological studies of this nature will contribute to facilitating the proper use of drugs after the launch and improving the quality of drug safety measures. Risk of granulocytopenia in patients treated with thiamazole stratified by the frequency of routine blood test blood tests at all previous periods (“All Conducted”) and one of previous periods (“Partly Conducted”). (Clin Pharmacol Ther. 2023; Table2 in 113: 924-931, Creative Common License http://creativecommons.org/licenses/by-nc-nd/4.0/)
元のページ ../index.html#19